Patti (UniCt): “Italy is a leader in organizing multiple sclerosis treatment”

From a clinical point of view, the therapeutic evaluation and, therefore, the ability to offer patients therapies capable of responding to their needs at 360 degrees is a “crucial point, especially at a time when we live in a country developed for the treatment of multiple sclerosis like Italy, which can offer its patients at least 20 drugs already used for the treatment of this disease, and has cutting-edge centers for the diagnosis and treatment of multiple sclerosis. It is in fact important to underline that the Italy is a world leader in terms of organizing the care of patients with this pathology.” Francesco Patti, professor of Neurology at the University of Catania, said this on the sidelines of the 'Space of care: as one for patients' event, organized in Milan by Merck and dedicated to new therapeutic frontiers for the treatment of highly relapsing multiple sclerosis. active.

“In such an important scenario, having many therapeutic solutions available – underlines Patti – choosing the most suitable drug for the patient constitutes a great opportunity. Especially in relation to what the patient's plan and lifestyle may be, for example the desire to create a family. The drug cladribine has a high efficacy profile and a very high safety profile”.

In treatment with cladribine, the specialist highlights, “there is no increased risk of infections and immuno-surveillance is high because the specific effect on the subtypes of immune cells is peculiar and does not determine a reduction in immunoglobulins, as instead we observe when we expose the patient to effective immunosuppressive therapies, but with continuous immunosuppression.” Cladribine, concludes Patti, also offers a notable advantage in the management of therapy, improving the patient's quality of life “thanks to its oral administration for a few days a week over a total period of 2 years, a period in which the patient will have performed diagnostic tests and blood products. Having a drug with these characteristics available means emphasizing the personalization of care and patient participation.”